Icardi A, Paoletti E, Molinelli G
Divisione de Nefrologia e Dialisi, Ospedale S. Martino, Genova, Italy.
Adv Perit Dial. 1990;6:292-5.
Recombinant erythropoietin (R-EPO) administered i.v. is effective in correcting anemia in patients on hemodialysis (HD). As subcutaneous (s.c.) or intraperitoneal (i.p.) dosing would be preferable in CAPD patients, we have evaluated its efficacy when given by these routes. Sixteen CAPD patients (mean Hb 7.3 +/- 1.6 g/dl) have been divided into two groups: group A received s.c. self-administered R-EPO (starting dose 92 +/- 35 U/kg/week) two times a week; in group B R-EPO was given i.p. (170 +/- 42 U/kg/week) thrice weekly. The observation period lasted about 12 months. All patients reached a target Hb greater than 10 g/dl. Group A achieved a full response within 9 +/- 2 weeks, group B within 13 +/- 1.7 (p less than 0.005). In group A the starting R-EPO dose was not changed; in group B it was increased to 225 +/- 45 U/kg/week. We observed no differences in the incidence of peritonitis in the two groups. Our findings show that both R-EPO administration routes are safe and efficient in correcting anemia in patients on CAPD. A shorter period of treatment and lower doses of R-EPO seem to be required to achieve the same target Hb level when using the s.c. rather than the i.p. application route.
静脉注射重组促红细胞生成素（R-EPO）对血液透析（HD）患者的贫血有纠正作用。由于持续性非卧床腹膜透析（CAPD）患者采用皮下（s.c.）或腹腔内（i.p.）给药更为合适，我们评估了通过这些途径给药时的疗效。16例CAPD患者（平均血红蛋白7.3±1.6 g/dl）被分为两组：A组患者每周两次自行皮下注射R-EPO（起始剂量92±35 U/kg/周）；B组患者每周三次腹腔内注射R-EPO（170±42 U/kg/周）。观察期持续约12个月。所有患者的血红蛋白均达到大于10 g/dl的目标值。A组在9±2周内达到完全缓解，B组在13±1.7周内达到完全缓解（p<0.005）。A组的起始R-EPO剂量未改变；B组的剂量增加至225±45 U/kg/周。我们观察到两组腹膜炎的发生率无差异。我们的研究结果表明，两种R-EPO给药途径对CAPD患者贫血的纠正都是安全有效的。与腹腔内给药途径相比，采用皮下给药途径似乎需要更短的治疗时间和更低剂量的R-EPO来达到相同的血红蛋白目标水平。
